发布求助
文献互助 智能选刊 最新文献

Annual review of pharmacology and toxicology最新文献

筛选
英文 中文
Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch. 专门的促解介质在疼痛和瘙痒控制中的解毒药理学作用。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-084047
Ru-Rong Ji
{"title":"Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch.","authors":"Ru-Rong Ji","doi":"10.1146/annurev-pharmtox-051921-084047","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-051921-084047","url":null,"abstract":"<p><p>Specialized pro-resolving mediators (SPMs), including resolvins, protectins, and maresins, are endogenous lipid mediators that are synthesized from omega-3 polyunsaturated fatty acids during the acute phase or resolution phase of inflammation. Synthetic SPMs possess broad safety profiles and exhibit potent actions in resolving inflammation in preclinical models. Accumulating evidence in the past decade has demonstrated powerful analgesia of exogenous SPMs in rodent models of inflammatory, neuropathic, and cancer pain. Furthermore, endogenous SPMs are produced by sham surgery and neuromodulation (e.g., vagus nerve stimulation). SPMs produce their beneficial actions through multiple G protein-coupled receptors, expressed by immune cells, glial cells, and neurons. Notably, loss of SPM receptors impairs the resolution of pain. I also highlight the emerging role of SPMs in the control of itch. Pharmacological targeting of SPMs or SPM receptors has the potential to lead to novel therapeutics for pain and itch as emerging approaches in resolution pharmacology.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"273-293"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290889/pdf/nihms-1907094.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9706294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Lysosomal Ion Channels: What Are They Good For and Are They Druggable Targets? 溶酶体离子通道:它们有什么好处，它们是可药物靶点吗?
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-013755
Erika Riederer, Chunlei Cang, Dejian Ren
{"title":"Lysosomal Ion Channels: What Are They Good For and Are They Druggable Targets?","authors":"Erika Riederer,&nbsp;Chunlei Cang,&nbsp;Dejian Ren","doi":"10.1146/annurev-pharmtox-051921-013755","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-051921-013755","url":null,"abstract":"<p><p>Lysosomes play fundamental roles in material digestion, cellular clearance, recycling, exocytosis, wound repair, Ca<sup>2+</sup> signaling, nutrient signaling, and gene expression regulation. The organelle also serves as a hub for important signaling networks involving the mTOR and AKT kinases. Electrophysiological recording and molecular and structural studies in the past decade have uncovered several unique lysosomal ion channels and transporters, including TPCs, TMEM175, TRPMLs, CLN7, and CLC-7. They underlie the organelle's permeability to major ions, including K<sup>+</sup>, Na<sup>+</sup>, H<sup>+</sup>, Ca<sup>2+</sup>, and Cl<sup>-</sup>. The channels are regulated by numerous cellular factors, ranging from H<sup>+</sup> in the lumen and voltage across the lysosomal membrane to ATP in the cytosol to growth factors outside the cell. Genetic variations in the channel/transporter genes are associated with diseases that include lysosomal storage diseases and neurodegenerative diseases. Recent studies with human genetics and channel activators suggest that lysosomal channels may be attractive targets for the development of therapeutics for the prevention of and intervention in human diseases.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"19-41"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10570683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Personalized Therapeutics for KATP-Dependent Pathologies. 针对 KATP 依赖性病症的个性化疗法。
IF 11.2 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 Epub Date: 2022-09-28 DOI: 10.1146/annurev-pharmtox-051921-123023
Colin G Nichols
{"title":"Personalized Therapeutics for K<sub>ATP</sub>-Dependent Pathologies.","authors":"Colin G Nichols","doi":"10.1146/annurev-pharmtox-051921-123023","DOIUrl":"10.1146/annurev-pharmtox-051921-123023","url":null,"abstract":"<p><p>Ubiquitously expressed throughout the body, ATP-sensitive potassium (K<sub>ATP</sub>) channels couple cellular metabolism to electrical activity in multiple tissues; their unique assembly as four Kir6 pore-forming subunits and four sulfonylurea receptor (SUR) subunits has resulted in a large armory of selective channel opener and inhibitor drugs. The spectrum of monogenic pathologies that result from gain- or loss-of-function mutations in these channels, and the potential for therapeutic correction of these pathologies, is now clear. However, while available drugs can be effective treatments for specific pathologies, cross-reactivity with the other Kir6 or SUR subfamily members can result in drug-induced versions of each pathology and may limit therapeutic usefulness. This review discusses the background to K<sub>ATP</sub> channel physiology, pathology, and pharmacology and considers the potential for more specific or effective therapeutic agents.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"541-563"},"PeriodicalIF":11.2,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868118/pdf/nihms-1854017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10741354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age-Related Perioperative Neurocognitive Disorders: Experimental Models and Druggable Targets. 年龄相关围手术期神经认知障碍:实验模型和药物靶点。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-112525
Odmara L Barreto Chang, Katherine L Possin, Mervyn Maze
{"title":"Age-Related Perioperative Neurocognitive Disorders: Experimental Models and Druggable Targets.","authors":"Odmara L Barreto Chang,&nbsp;Katherine L Possin,&nbsp;Mervyn Maze","doi":"10.1146/annurev-pharmtox-051921-112525","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-051921-112525","url":null,"abstract":"<p><p>With the worldwide increase in life span, surgical patients are becoming older and have a greater propensity for postoperative cognitive impairment, either new onset or through deterioration of an existing condition; in both conditions, knowledge of the patient's preoperative cognitive function and postoperative cognitive trajectory is imperative. We describe the clinical utility of a tablet-based technique for rapid assessment of the memory and attentiveness domains required for executive function. The pathogenic mechanisms for perioperative neurocognitive disorders have been investigated in animal models in which excessive and/or prolonged postoperative neuroinflammation has emerged as a likely contender. The cellular and molecular species involved in postoperative neuroinflammation are the putative targets for future therapeutic interventions that are efficacious and do not interfere with the surgical patient's healing process.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"321-340"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9136374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Lipoxin Mimetics and the Resolution of Inflammation. 脂质毒素模拟物与炎症的缓解
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-085407
Catherine Godson, Patrick Guiry, Eoin Brennan
{"title":"Lipoxin Mimetics and the Resolution of Inflammation.","authors":"Catherine Godson, Patrick Guiry, Eoin Brennan","doi":"10.1146/annurev-pharmtox-051921-085407","DOIUrl":"10.1146/annurev-pharmtox-051921-085407","url":null,"abstract":"<p><p>Inflammation and its timely resolution are critical to ensure effective host defense and appropriate tissue repair after injury and or infection. Chronic, unresolved inflammation typifies many prevalent pathologies. The key mediators that initiate and drive the inflammatory response are well defined and targeted by conventional anti-inflammatory therapeutics. More recently, there is a growing appreciation that specific mediators, including arachidonate-derived lipoxins, are generated in self-limiting inflammatory responses to promote the resolution of inflammation and endogenous repair mechanisms without compromising host defense. We discuss the proresolving biological actions of lipoxins and recent efforts to harness their therapeutic potential through the development of novel, potent lipoxin mimetics generated via efficient, modular stereoselective synthetic pathways. We consider the evidence that lipoxin mimetics may have applications in limiting inflammation and reversing fibrosis and the underlying mechanisms.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"429-448"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9126124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health. 长链欧米茄-3 多不饱和脂肪酸对心血管健康的利弊。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-090208
Ivana Djuricic, Philip C Calder
{"title":"Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health.","authors":"Ivana Djuricic, Philip C Calder","doi":"10.1146/annurev-pharmtox-051921-090208","DOIUrl":"10.1146/annurev-pharmtox-051921-090208","url":null,"abstract":"<p><p>The long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in seafood, supplements, and concentrated pharmaceutical preparations. Prospective cohort studies demonstrate an association between higher intakes of EPA+DHA or higher levels of EPA and DHA in the body and lower risk of developing cardiovascular disease (CVD), especially coronary heart disease and myocardial infarction, and of cardiovascular mortality in the general population. The cardioprotective effect of EPA and DHA is due to the beneficial modulation of a number of risk factors for CVD. Some large trials support the use of EPA+DHA (or EPA alone) in high-risk patients, although the evidence is inconsistent. This review presents key studies of EPA and DHA in the primary and secondary prevention of CVD, briefly describes potential mechanisms of action, and discusses recently published RCTs and meta-analyses. Potential adverse aspects of long-chain omega-3 fatty acids in relation to CVD are discussed.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"383-406"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9126125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention. 一天一片阿司匹林:新的药理发展和癌症化学预防。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-052020-023107
David G Menter, Robert S Bresalier
{"title":"An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention.","authors":"David G Menter,&nbsp;Robert S Bresalier","doi":"10.1146/annurev-pharmtox-052020-023107","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-052020-023107","url":null,"abstract":"<p><p>Chemoprevention refers to the use of natural or synthetic agents to reverse, suppress, or prevent the progression or recurrence of cancer. A large body of preclinical and clinical data suggest the ability of aspirin to prevent precursor lesions and cancers, but much of the clinical data are inferential and based on descriptive epidemiology, case control, and cohort studies or studies designed to answer other questions (e.g., cardiovascular mortality). Multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers but may also cause other effects depending on the tissue or disease and organ site in question. The best-known biological targets of aspirin are cyclooxygenases, which drive a wide variety of functions, including hemostasis, inflammation, and immune modulation. Newly recognized molecular and cellular interactions suggest additional modifiable functional targets, and the existence of consensus molecular cancer subtypes suggests that aspirin may have differential effects based on tumor heterogeneity. This review focuses on new pharmacological developments and innovations in biopharmacology that clarify the potential role of aspirin in cancer chemoprevention.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"165-186"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10572248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Pharmacogenetics of Antiplatelet Therapy. 抗血小板疗法的药物遗传学。
IF 11.2 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 Epub Date: 2022-01-08 DOI: 10.1146/annurev-pharmtox-051921-092701
Matteo Castrichini, Jasmine A Luzum, Naveen Pereira
{"title":"Pharmacogenetics of Antiplatelet Therapy.","authors":"Matteo Castrichini, Jasmine A Luzum, Naveen Pereira","doi":"10.1146/annurev-pharmtox-051921-092701","DOIUrl":"10.1146/annurev-pharmtox-051921-092701","url":null,"abstract":"<p><p>Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in <i>CYP2C19</i> may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function <i>CYP2C19</i> alleles and thus have reduced active clopidogrel metabolites, high on-treatment platelet reactivity, and increased ischemic risk. Prospective studies have examined the utility of <i>CYP2C19</i> genetic testing to guide antiplatelet therapy, and more recently published meta-analyses suggest that pharmacogenetics represents a key treatment strategy to individualize antiplatelet therapy. Rapid genetic tests, including bedside genotyping platforms that are validated and have high reproducibility, are available to guide selection of P2Y12 inhibitors in clinical practice. The aim of this review is to provide an overview of the background and rationale for the role of a guided antiplatelet approach to enhance patient care.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"211-229"},"PeriodicalIF":11.2,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10606443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Delightful Trip Along the Pathway of Cannabinoid and Endocannabinoid Chemistry and Pharmacology. 沿着大麻素和内源性大麻素化学和药理学途径的愉快旅行。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-051921-083709
Raphael Mechoulam
{"title":"A Delightful Trip Along the Pathway of Cannabinoid and Endocannabinoid Chemistry and Pharmacology.","authors":"Raphael Mechoulam","doi":"10.1146/annurev-pharmtox-051921-083709","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-051921-083709","url":null,"abstract":"<p><p>After a traumatic childhood in Europe during the Second World War, I found that scientific research in Israel was a pleasure beyond my expectations. Over the last 65 year, I have worked on the chemistry and pharmacology of natural products. During the last few decades, most of my research has been on plant cannabinoids, the endogenous cannabinoids arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol, and endogenous anandamide-like compounds, all of which are involved in a wide spectrum of physiological reactions. Two plant cannabinoids, Δ<sup>9</sup>-tetrahydrocannabinol and cannabidiol, are approved drugs. However, the endogenous cannabinoids and the anandamide-like constituents have not yet been well investigated in humans. For me, intellectual freedom-the ability to do research based on my own scientific interests-has been the most satisfying part of my working life. Looking back over the 91 years of my long life, I conclude that I have been lucky, very lucky, both personally and scientifically.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"1-13"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10624816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. 超越勃起功能障碍:cgmp特异性磷酸二酯酶5抑制剂治疗其他临床疾病。
IF 12.5 1区 医学
Annual review of pharmacology and toxicology Pub Date : 2023-01-20 DOI: 10.1146/annurev-pharmtox-040122-034745
Arun Samidurai, Lei Xi, Anindita Das, Rakesh C Kukreja
{"title":"Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.","authors":"Arun Samidurai,&nbsp;Lei Xi,&nbsp;Anindita Das,&nbsp;Rakesh C Kukreja","doi":"10.1146/annurev-pharmtox-040122-034745","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-040122-034745","url":null,"abstract":"<p><p>Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger, mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is one of the 11 members of the cyclic nucleotide phosphodiesterase (PDE) family that specifically targets cGMP generated by nitric oxide-driven activation of the soluble guanylyl cyclase. PDE5 inhibitors, including sildenafil and tadalafil, are widely used for the treatment of erectile dysfunction, pulmonary arterial hypertension, and certain urological disorders. Preclinical studies have shown promising effects of PDE5 inhibitors in the treatment of myocardial infarction, cardiac hypertrophy, heart failure, cancer and anticancer-drug-associated cardiotoxicity, diabetes, Duchenne muscular dystrophy, Alzheimer's disease, and other aging-related conditions. Many clinical trials with PDE5 inhibitors have focused on the potential cardiovascular, anticancer, and neurological benefits. In this review, we provide an overview of the current state of knowledge on PDE5 inhibitors and their potential therapeutic indications for various clinical disorders beyond erectile dysfunction.</p>","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"63 ","pages":"585-615"},"PeriodicalIF":12.5,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9792553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信